文献速递角膜与眼表疾病

他汀类药物使用与干眼病的关联:系统综述与荟萃分析

Association Between Statin Use and Dry Eye Disease: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2026-06-22

该系统综述与荟萃分析纳入6项观察性研究(n=560,821),评估他汀使用与干眼病(DED)的文献汇总关联。随机效应荟萃分析显示他汀与DED存在显著正关联(OR 1.09,95%CI 1.05-1.13,P<.001),绝对风险差为每1000人增加10.2例DED(95%CI 5.5-15.2),但证据确定性极低。作者建议对使用他汀且已有DED危险因素的患者监测眼表症状。

要点

  • 他汀使用与干眼病风险轻度增加相关(OR 1.09,95%CI 1.05-1.13)。
  • 绝对风险差为每1000人增加10.2例干眼病(95%CI 5.5-15.2)。
  • 证据确定性极低,主要因研究设计局限和严重不一致性。

核心结论

  • 他汀使用与干眼病存在小但统计学显著的正关联,但证据确定性极低。

研究设计与样本

  • 纳入6项观察性研究,总样本n=560,821,其中他汀使用者356,012/559,141(63.7%)。
  • 采用逆方差加权随机效应荟萃分析合并OR及95%CI,使用ROBINS-E评估偏倚风险,GRADE框架评价证据确定性。

主要发现

  • 合并分析显示他汀与DED显著正关联(OR 1.09,95%CI 1.05-1.13,P<.001)。
  • 绝对风险差为每1000人增加10.2例DED(95%CI 5.5-15.2)。
  • 亚组及敏感性分析(偏倚风险P=.123、结局确认方法P=.737、效应估计类型P=.496)及留一法分析均未显示效应修饰,关联方向一致。

关键数值与推荐

  • 他汀使用与DED关联的合并OR为1.09(95%CI 1.05-1.13,P<.001)。
  • 绝对风险差为每1000人增加10.2例DED(95%CI 5.5-15.2)。
  • 证据确定性为极低,因研究设计局限和严重不一致性。

临床怎么用

  • 对使用他汀且已有DED危险因素的患者,应监测并教育其关注眼表症状。
  • 未来研究应使用标准化DED诊断标准,探究他汀剂量、类型和疗程的影响。

局限性

  • 证据确定性极低,主要因研究设计局限和严重不一致性。
  • 纳入研究均为观察性研究,无法排除残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: This systematic review and meta-analysis evaluated the literature-pooled association between statins and dry eye disease (DED). CLINICAL RELEVANCE: Statins, a common treatment modality for dyslipidemia, have been proposed as a potential contributor to DED via their activity in meibomian gland epithelial cells. However, single studies show mixed evidence, and there remains an unmet clinical need to clarify whether statin exposure is associated with DED. METHODS: This review was reported in accordance with the Preferred Reporting Items for Systematic Reviews of Interventions (PRISMA) 2020 statement and was registered a priori on PROSPERO (CRD420251238004). Ovid MEDLINE, Embase, CINAHL, Web of Science, CENTRAL, and the reference lists of relevant reviews were searched from inception to November 2025 for studies reporting the association between statin use and DED. Random-effects meta-analysis using inverse-variance weighting was conducted to pool effect estimates as odds ratios with 95% confidence intervals (CIs). Study risk of bias was appraised using the ROBINS-E tool, and the certainty of the evidence was reported using the GRADE framework. RESULTS: Six observational studies were included in the meta-analysis (n = 560,821; 356,012/559,141 [63.7%] statin users). The pooled analysis revealed a significant positive association between statins and DED (odds ratio 1.09, 95% CI 1.05-1.13, P < .001), with an absolute risk difference of 10.2 more DED cases per 1000 (95% CI 5.5 more to 15.2 more). This result was derived from very low-certainty evidence given limitations in study design and serious inconsistency. Subgroup and sensitivity analyses for risk of bias (P = .123), method of outcome ascertainment (P = .737), type of effect estimate (P = .496), and leave-one-out analyses showed no evidence of effect modification and demonstrated consistent direction of association across studies. CONCLUSION: Statin use was associated with a small but statistically significant increase in DED, limited by very low-certainty evidence. Physicians should monitor for and educate patients on ocular surface symptoms in patients using statins with pre-existing DED risk factors. Future studies should use standardized DED diagnostic criteria to investigate the impact of statin dose, type, and duration to better characterize this potential association.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gou D, Qiu W, Chang V, et al. Association Between Statin Use and Dry Eye Disease: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2026. PMID: 42331129. doi:10.1016/j.ajo.2026.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。